Tisagenlecleucel
- Generic Name
- Tisagenlecleucel
- Brand Names
- Kymriah
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1823078-37-0
- Unique Ingredient Identifier
- Q6C9WHR03O
- Background
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient a...
- Indication
Tisagenlecleucel is indicated for use in individuals aged 25 years and younger with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
...
- Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Follicular Lymphoma, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Follicular Lymphoma, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath